09:03 AM EDT, 09/27/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday updated results from the investigational phase 1b study assessing the combination of Talvey and Tecvayli showed "high" response rates in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease.

The overall response rate was 79.5% at data cutoff for patients treated with the combination, the safety profile of which was consistent with Talvey and Tecvayli monotherapies, the company said.

Multiple myeloma is a cancer that affects white blood cells found in bone marrow.

Price: 161.33, Change: -0.06, Percent Change: -0.04